Advertisement

Topics

Search Results for "Xarelto Vs Pradaxa"

05:36 EDT 27th June 2016 | BioPortfolio

Matching Channels

Rivaroxaban

Rivaroxaban is the most broadly indicated novel oral anticoagulant and is marketed under the brand name Xarelto®. To date, Xarelto has been approved for use in the following indications across t...

Matching News

With First Trials On Horizon, Value Of Growing Philly Xarelto Claims Uncertain

It might be more than a year from now, but litigation centered on the blood thinner Xarelto could eventually come to trial in Philadelphia courtrooms – and one attorney says the thousands of cases f...

Xarelto Lawsuits Now Exceed 3,000 in Number

NEW ORLEANS, Feb. 11, 2016 /PRNewswire/ -- Legal-Bay LLC, The Lawsuit Settlement Funding Company, reported today that the number of filed lawsuits against Bayer and Johnson & Johnson's subsidiary,...

Lawsuitsettlementnews.com Says Xarelto Lawsuits Rise as Court Begins Process to Select Cases for Initial Bellwether Trials

NEW ORLEANS, Jan. 18, 2016 /PRNewswire/ -- MT Services LLC, a Lawsuit Settlement News Reporting Company which operates lawsuitsettlementnews.com, reports today that Xarelto lawsuits have risen to...

Xarelto Lawsuits Rise as First Bellwether Cases Are Selected

NEW ORLEANS, Jan. 13, 2016 /PRNewswire/ -- Legal-Bay LLC, The Lawsuit Settlement Funding Company, reports today that the court has started the process of selecting 40 cases for the Xarelto multid...

Relief For Pradaxa: Praxbind Gets HTA Green Light

Pradaxa has so far not fared as well as the competition in global markets because it has a twice-daily dosing schedule and has higher rates of gastrointestinal intolerability, bleeding, and myocardial...

EMA offers reassurance after Xarelto trial fault

Stroke-prevention drug Xarelto (rivaroxaban) can still be used safely even though a faulty device was…

Real-World Analysis of more than 44,000 Patients Reinforces Safety and Effectiveness of Pradaxa® in Routine Clinical Care

• New data show Pradaxa® reduced stroke risk and major bleeding compared to warfarin in patients with non-valvular atrial fibrillation1 • Pradaxa® was associated with 28% and 26% reductions in s...

News and press releases: EMA concludes defective device in ROCKET study does not impact Xarelto’s safety

Study is the main trial supporting use of Xarelto in atrial fibrillation

Matching PubMed Articles

Praxbind Available as Antidote to Bleeding from Pradaxa.

Waiting for the Antidote: The Journey of Idarucizumab as a Potential Specific Reversal Agent for Dabigatran (Pradaxa).

Waiting for the Antidote: The Journey of Idarucizumab as a Potential Specific Reversal Agent for Dabigatran (Pradaxa).

Pharmaceutical Approval Update.

Idarucizumab (Praxbind) to reverse the anticoagulant effects of dabigatran (Pradaxa); aripiprazole lauroxil (Aristada) for the treatment of schizophrenia; and insulin degludec injection (Tresiba) for ...

Effects of Rivaroxaban Therapy on ROTEM Coagulation Parameters in Patients with Venous Thromboembolism.

Rivaroxaban (Xarelto) does not require routine coagulation monitoring; however, in certain clinical situations (overdose, drug accumulation, urgent surgery) measurement of its plasma concentration is ...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement